ES2991516T3 - Métodos para tratar tumores de restos adrenales testiculares y ováricos - Google Patents
Métodos para tratar tumores de restos adrenales testiculares y ováricos Download PDFInfo
- Publication number
- ES2991516T3 ES2991516T3 ES19793181T ES19793181T ES2991516T3 ES 2991516 T3 ES2991516 T3 ES 2991516T3 ES 19793181 T ES19793181 T ES 19793181T ES 19793181 T ES19793181 T ES 19793181T ES 2991516 T3 ES2991516 T3 ES 2991516T3
- Authority
- ES
- Spain
- Prior art keywords
- approximately
- compound
- pharmaceutically acceptable
- acceptable salt
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862663951P | 2018-04-27 | 2018-04-27 | |
| US201962822815P | 2019-03-23 | 2019-03-23 | |
| PCT/US2019/029486 WO2019210266A1 (en) | 2018-04-27 | 2019-04-26 | Methods for treating testicular and ovarian adrenal rest tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2991516T3 true ES2991516T3 (es) | 2024-12-03 |
Family
ID=68295784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19793181T Active ES2991516T3 (es) | 2018-04-27 | 2019-04-26 | Métodos para tratar tumores de restos adrenales testiculares y ováricos |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US11304950B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3784233B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7427655B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112423747A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2019260793B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020024062A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3098562A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2991516T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020011344A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019210266A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210064407A (ko) | 2014-01-21 | 2021-06-02 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 선천성 부신 과형성 치료를 위한 crf1 수용체 길항제 |
| BR112020002967A2 (pt) | 2017-08-14 | 2020-08-11 | Spruce Biosciences, Inc. | antagonistas de receptor de fator de liberação de corticotropina |
| MX2020011344A (es) | 2018-04-27 | 2021-02-09 | Spruce Biosciences Inc | Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios. |
| PL3984523T3 (pl) | 2018-12-07 | 2026-02-02 | Neurocrine Biosciences, Inc. | Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy |
| KR20220052927A (ko) | 2019-07-19 | 2022-04-28 | 스프루스 바이오사이언시스 인코포레이티드 | 선천성 부신 증식증의 치료 방법 |
| US12383536B2 (en) | 2019-09-27 | 2025-08-12 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods of use |
| ES3039926T3 (en) | 2019-12-04 | 2025-10-27 | Neurocrine Biosciences Inc | Crf receptor antagonists and methods of use |
| JP2023537598A (ja) | 2020-08-12 | 2023-09-04 | スプルース バイオサイエンシーズ,インク. | 多嚢胞性卵巣症候群を処置するための方法および組成物 |
| US20240024330A1 (en) * | 2020-08-26 | 2024-01-25 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
| US11708372B2 (en) * | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
| EP4402142A4 (en) * | 2021-11-19 | 2025-07-23 | Spruce Biosciences Inc | CRYSTALLINE COMPOSITION OF TILDACERFONT AND ITS METHODS OF USE AND PREPARATION |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| BR9307646A (pt) | 1992-12-17 | 1999-05-25 | Pfizer | Pirrolopirimidinas como antagonistas de crf |
| JPH0971528A (ja) * | 1995-07-05 | 1997-03-18 | Hayashibara Biochem Lab Inc | 抗腫瘍剤 |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| ES2168237T3 (es) | 1996-02-07 | 2007-04-01 | Neurocrine Biosciences, Inc. | Pirazolopirimidinas como antagonistas de receptores de crf. |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| AU747708B2 (en) | 1996-07-24 | 2002-05-23 | Du Pont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| PL332040A1 (en) | 1996-08-28 | 1999-08-16 | Pfizer | Substitution 6,5-heterobicyclic derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| IL137019A (en) | 1998-01-28 | 2010-11-30 | Du Pont Pharm Co | 2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| EP1040831A3 (en) | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death |
| AU4203500A (en) | 1999-04-06 | 2000-10-23 | Du Pont Pharmaceuticals Company | Pyrazolopyrimidines as crf antagonists |
| FR2796380B3 (fr) | 1999-07-15 | 2001-08-17 | Sanofi Synthelabo | Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant |
| YU23602A (sh) | 1999-09-30 | 2004-09-03 | Neurogen Corporation | Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini |
| HRP20010582A2 (en) | 1999-12-08 | 2002-08-31 | Pharmacia Corp | Valdecoxib compositions |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| KR20030014425A (ko) | 2000-07-07 | 2003-02-17 | 앤지오젠 파마슈티칼스 리미티드 | 혈관 손상제인 콜치놀 유도체 |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| ES2282401T3 (es) | 2001-03-13 | 2007-10-16 | Bristol-Myers Squibb Pharma Company | 4-(2-butilamino)-2,7-dimetil-8-(2-metil-6-metoxipirid-3-il) pirazolo - 1,5-a-1,3,5-triazina, sus enantiomeros y sales farmaceuticamente aceptables como ligandos del receptor del factor liberador de croticotropina. |
| WO2005020910A2 (en) | 2003-08-27 | 2005-03-10 | Pharmacia Corporation | Cyclooxygenase-2 selective inhibitor and corticotropin releasing factor antagonist compositions for treating ischemic mediated cns disorders or injuries |
| US8304431B2 (en) | 2003-12-02 | 2012-11-06 | Pharmaneuroboost N.V. | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| JP4926720B2 (ja) | 2003-12-22 | 2012-05-09 | スミスクライン ビーチャム (コーク) リミテッド | Crf受容体アンタゴニストおよびそれらに関連する方法 |
| JP2008503444A (ja) | 2004-02-13 | 2008-02-07 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | Crf受容体アンタゴニスト、その調製法、その医薬組成物およびその使用 |
| CA2556160A1 (en) | 2004-02-13 | 2005-09-01 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists |
| US20060078623A1 (en) | 2004-08-13 | 2006-04-13 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| CN101142217B (zh) | 2005-03-21 | 2010-12-08 | 伊莱利利公司 | 咪唑并哒嗪化合物 |
| CA2644445A1 (en) * | 2006-03-29 | 2007-10-04 | Velacor Therapeutics Pty Ltd | Inorganic selenium for treatment of benign tumors |
| CN101516835A (zh) | 2006-07-19 | 2009-08-26 | 俄亥俄州立大学研究基金会 | 选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途 |
| MX2009003098A (es) | 2006-09-20 | 2009-04-01 | Lilly Co Eli | Compuestos de tiofen pirazolopirimidina. |
| KR101088239B1 (ko) * | 2006-09-20 | 2011-11-30 | 일라이 릴리 앤드 캄파니 | Crf1 수용체 길항제로서의 티아졸 피라졸로피리미딘 |
| US8952207B2 (en) | 2007-09-11 | 2015-02-10 | The University Of Houston System | Copper-catalyzed C—H bond arylation |
| US8318813B2 (en) | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
| US20100203048A1 (en) * | 2008-04-30 | 2010-08-12 | Stephen Evans-Freke | Methods of using corticotropin-releasing factor for the use of the treatment of cancer |
| TWI432435B (zh) | 2008-10-02 | 2014-04-01 | Lilly Co Eli | 作為合成中間物之噻唑基-吡唑并嘧啶化合物及相關合成方法 |
| EP4718073A3 (en) | 2008-12-24 | 2026-07-29 | Quest Diagnostics Investments LLC | Mass spectrometry assay for congenital adrenal hyperplasia |
| US20110160168A1 (en) | 2009-12-31 | 2011-06-30 | Differential Drug Development Associates, Llc | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
| US9750568B2 (en) | 2012-03-08 | 2017-09-05 | Medtronic Ardian Luxembourg S.A.R.L. | Ovarian neuromodulation and associated systems and methods |
| JP2015516979A (ja) | 2012-04-23 | 2015-06-18 | ホルスボールマッシュマイヤー ニューロケミー ゲーエムベーハーHolsboermaschmeyer Neurochemie Gmbh | Crh過剰活性を有する患者の治療に用いるためのcrhr1アンタゴニスト |
| KR20210064407A (ko) * | 2014-01-21 | 2021-06-02 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 선천성 부신 과형성 치료를 위한 crf1 수용체 길항제 |
| ES2964948T3 (es) | 2015-03-31 | 2024-04-10 | May Health Us Inc | Métodos y sistemas para la manipulación de tejidos ováricos |
| BR112020002967A2 (pt) | 2017-08-14 | 2020-08-11 | Spruce Biosciences, Inc. | antagonistas de receptor de fator de liberação de corticotropina |
| TWI803504B (zh) | 2017-08-14 | 2023-06-01 | 美商雲杉生物科技股份有限公司 | 促皮質素釋放因子受體拮抗劑 |
| MX2020011344A (es) | 2018-04-27 | 2021-02-09 | Spruce Biosciences Inc | Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios. |
| PL3984523T3 (pl) | 2018-12-07 | 2026-02-02 | Neurocrine Biosciences, Inc. | Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy |
| US20200255436A1 (en) | 2019-02-12 | 2020-08-13 | Spruce Biosciences, Inc. | Corticotropin releasing factor receptor antagonists |
| KR20220052927A (ko) | 2019-07-19 | 2022-04-28 | 스프루스 바이오사이언시스 인코포레이티드 | 선천성 부신 증식증의 치료 방법 |
| JP2023537598A (ja) | 2020-08-12 | 2023-09-04 | スプルース バイオサイエンシーズ,インク. | 多嚢胞性卵巣症候群を処置するための方法および組成物 |
| EP4402142A4 (en) | 2021-11-19 | 2025-07-23 | Spruce Biosciences Inc | CRYSTALLINE COMPOSITION OF TILDACERFONT AND ITS METHODS OF USE AND PREPARATION |
| US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
-
2019
- 2019-04-26 MX MX2020011344A patent/MX2020011344A/es unknown
- 2019-04-26 EP EP19793181.9A patent/EP3784233B1/en not_active Revoked
- 2019-04-26 EP EP24179880.0A patent/EP4438124A3/en not_active Withdrawn
- 2019-04-26 BR BR112020024062-1A patent/BR112020024062A2/pt not_active Application Discontinuation
- 2019-04-26 ES ES19793181T patent/ES2991516T3/es active Active
- 2019-04-26 WO PCT/US2019/029486 patent/WO2019210266A1/en not_active Ceased
- 2019-04-26 CA CA3098562A patent/CA3098562A1/en active Pending
- 2019-04-26 EP EP25182968.5A patent/EP4643950A3/en active Pending
- 2019-04-26 AU AU2019260793A patent/AU2019260793B2/en not_active Revoked
- 2019-04-26 JP JP2021509725A patent/JP7427655B2/ja active Active
- 2019-04-26 CN CN201980043623.8A patent/CN112423747A/zh active Pending
-
2020
- 2020-10-27 US US17/081,694 patent/US11304950B2/en active Active
-
2022
- 2022-02-08 US US17/667,285 patent/US20220211711A1/en not_active Abandoned
-
2023
- 2023-05-17 AU AU2023203095A patent/AU2023203095A1/en not_active Abandoned
-
2024
- 2024-11-08 US US18/941,832 patent/US20250064812A1/en active Pending
-
2025
- 2025-01-31 US US19/043,264 patent/US12569490B2/en active Active
- 2025-01-31 US US19/043,275 patent/US12569491B2/en active Active
- 2025-01-31 US US19/043,303 patent/US12576084B2/en active Active
- 2025-06-23 AU AU2025204720A patent/AU2025204720A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12576084B2 (en) | 2026-03-17 |
| US11304950B2 (en) | 2022-04-19 |
| EP4438124A3 (en) | 2024-12-18 |
| AU2019260793A1 (en) | 2020-12-17 |
| EP4643950A3 (en) | 2026-01-14 |
| JP7427655B2 (ja) | 2024-02-05 |
| AU2025204720A1 (en) | 2025-07-10 |
| EP3784233B1 (en) | 2024-06-05 |
| EP4438124A2 (en) | 2024-10-02 |
| AU2023203095A1 (en) | 2023-06-08 |
| US20250064812A1 (en) | 2025-02-27 |
| US20250195527A1 (en) | 2025-06-19 |
| MX2020011344A (es) | 2021-02-09 |
| US20250177404A1 (en) | 2025-06-05 |
| EP3784233C0 (en) | 2024-06-05 |
| US12569490B2 (en) | 2026-03-10 |
| US12569491B2 (en) | 2026-03-10 |
| WO2019210266A1 (en) | 2019-10-31 |
| CA3098562A1 (en) | 2019-10-31 |
| EP3784233A1 (en) | 2021-03-03 |
| JP2021522340A (ja) | 2021-08-30 |
| EP3784233A4 (en) | 2022-03-02 |
| EP4643950A2 (en) | 2025-11-05 |
| BR112020024062A2 (pt) | 2021-02-09 |
| US20250177403A1 (en) | 2025-06-05 |
| US20210038604A1 (en) | 2021-02-11 |
| US20220211711A1 (en) | 2022-07-07 |
| CN112423747A (zh) | 2021-02-26 |
| AU2019260793B2 (en) | 2023-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12569491B2 (en) | Methods for treating testicular and ovarian adrenal rest tumors | |
| US11964941B2 (en) | 5-Bromo-indirubins | |
| AU2012341028B2 (en) | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof | |
| US11730736B2 (en) | Anticancer agents | |
| US11505523B2 (en) | HDAC8 inhibitors for treating cancer | |
| TWI877863B (zh) | 整合應激路徑之前藥調節劑 | |
| US20220274964A1 (en) | 5-bromo-indirubins | |
| HK40040045A (en) | Methods for treating testicular and ovarian adrenal rest tumors | |
| HK40040045B (en) | Methods for treating testicular and ovarian adrenal rest tumors |